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Ductal carcinoma in situ of the breast is associated with low mortality rates, but local relapse is a matter of concern in this
disease. Risk factors for local relapse include young age, close or positive margins, and tumor necrosis. Whole breast irradiation
followingbreast-conservingsurgeryforductalcarcinomainsitusigniﬁcantlyreducestheriskoflocalrelapseascomparedtobreast-
conservingsurgeryalone.Studiespointtosimilaroutcomesbetweenbreast-conservingsurgeryplusradiotherapyandmastectomy,
in the absence of extensive disease. A complementary boost to the surgical bed improves outcomes for patients with invasive breast
cancer. However, the eﬀect of this strategy has never been prospectively reported for ductal carcinoma in situ. Two randomized
controlled trials assessing this issue are ongoing. This paper represents an update on available literature about radiotherapy for
DCIS with a special focus on the role of a radiotherapy boost to the tumor bed.
1.Introduction
Ductal carcinoma in situ (DCIS) is a proliferation of malig-
nant cells inside galactophoric ducts without basal mem-
brane invasion. Its incidence has dramatically increased in
therecentyearsduetothewidespreaduseofmammographic
screening. Accounting for approximately 20 to 30% of the
breast cancer cases [1], DCIS is heterogeneous in clinical
presentation, varying from a palpable mass, mammographi-
cally detected tumor, or nipple discharge [2]. Despite a high
cure rate, invasive recurrence and death may occur in case
of insuﬃcient local treatment. Patients with clinically large,
multicentric, and extensive tumors are more likely to
undergo mastectomy than breast-conserving surgery (BCS),
because of a higher risk of recurrence [3]. Likewise, mas-
tectomy may be the preferred strategy in case of dif-
fuse suspicious-appearing microcalciﬁcations in the breast,
inability to obtain margin control by lumpectomy and/or
reexcision(s), medical contraindication to irradiation, and
when an unfavorable tumor-to-breast size ratio does not
permit margin-negative lumpectomy with cosmetically
acceptable results [4].
No randomized controlled trials comparing mastectomy
with more conserving management are available, but dif-
ferent studies point to similar outcomes between BCS plus
radiotherapyandmastectomy,whereasBCSalonetendstobe
inferior [5]. Therefore, BCS plus radiotherapy is an accepted
strategy when mastectomy can be avoided, in view of the
morbidity of radical surgery and the favorable prognosis of
such patients. A number of randomized controlled trials of
adjuvant radiotherapy have indeed demonstrated a reduced
risk of both invasive and local recurrences, as well as a low
risk of side eﬀects [6, 7].
A radiation boost to the tumor bed has been shown to
signiﬁcantly improve local control in patients with invasive
breast cancer [8, 9]. However, the usefulness of a boost has
not been so well assessed in the setting of DCIS, and pro-
spective studies are missing.
This paper aims at updating available literature on the
subject and at developing the rationale for randomized2 International Journal of Surgical Oncology
multicenter phase 3 studies assessing the role of surgical bed
boost following whole breast irradiation (WBI).
2. Risk Factors for Local Relapse following
Breast-Conserving Therapy
Several studies have attempted to identify the local recur-
rence risk factors following breast-conserving surgery [10].
Clinical factors have been determined by uni- and multivari-
ate analysis of randomized trials and multicenter retrospec-
tive studies. These ﬁndings suggest that a family history of
breast cancer, a young-onset disease, and a palpable tumor
of more than 1cm are factors that may adversely aﬀect local
control [11–13]. Moreover, the comedocarcinoma subtype,
a histopathology size greater than 10mm, necrosis, and pos-
itive margins have been shown to be statistically signiﬁcant
predictive factors for recurrence in women under 40 years
old [14].
Close or positive margins are considered to be risk
factors for recurrence, whether patients are irradiated or not.
In the B-24 and EORTC 10853 trials, although patients
were supposed to have free margins for inclusion [15, 16],
a central pathology review of the specimens found a sig-
niﬁcant amount of positive and unknown margins [17]. In
these trials, positive margins were found to be independent
factors for the development of local relapse after BCS [18].
According to the meta-analysis of Dunne et al., a margin
threshold of 2mm may be suﬃcient when BCS is combined
with RT [19].
Apart from margins status, tumor necrosis appears to be
an important relapse risk factor, even in multifactorial anal-
ysis [20]. The histological size, the Scarﬀ-Bloom-Richardson
grade, and the degree of diﬀerentiation are minor prognostic
factors. No prognostic biological or genetic factors have been
individualized so far in ductal carcinoma in situ [21].
3. The Inﬂuence of AdjuvantRadiotherapy in
the Conserving Treatment of DCIS
The role of WBI is to reduce the rate of local relapse and to
allow for breast conservation. Monocenter and multicenter
retrospective studies with 5 to 15 years of followup found
recurrence rates of about 7 to 17%. About half of recurrences
were invasive, and the metastatic rate was less than 10%.
Nevertheless, these studies had heterogeneous inclusion
criteria, surgical treatment, radiation dose, and followup
[22].
Four randomized controlled trials have assessed the role
of irradiation in this setting. A worldwide collaboration
group, the Early Breast Cancer Trialists’ Collaborative Group
(EBCTCG), has centrally reviewed these four trials to give an
updatedoverviewoftheimpactofradiotherapyinDCIS.The
latest report conﬁrmed a 15.2% reduction in the absolute
10-year risk of ipsilateral breast event, regardless of age
at diagnosis, extent of breast-conserving therapy, use of
tamoxifen, margin status, comedonecrosis, focality, grade, or
tumor size. The amount of risk reductionwashigher in older
women (>50 years). However, no signiﬁcant eﬀect on over-
all mortality or breast cancer mortality was found after a
followup of 10 years [7].
3.1. NSABP B17. The NSABP B17 trial was undertaken in
the United States and Canada from 1985 to 1990. The results
of this trial were ﬁrst published in 1993 and then updated
in 2001 [23, 24]. A total of 818 patients were randomized,
after initial lumpectomy for DCIS, to either surveillance or
WBI to 50Gy in 25 fractions without tumor bed boost. After
a mean followup of 129 months, a 57% reduction in the
risk of invasive and in situ breast recurrences was seen. No
diﬀerences in overall survival, metastatic, or contralateral
cancer rates were shown. A pooled analysis of this study
and of the NSABP B24 trial conﬁrmed a 52% reduction in
ipsilateral breast recurrence risk at 15 years when patients
were oﬀered radiation therapy [25].
3.2. EORTC 10853. This trial was conducted in Europe from
1986 to 1996 and accrued one thousand and ten DCIS
patients with free margins after lumpectomy. First analysis
afterafollowupof4.2yearsshowedasigniﬁcantreductionin
invasive relapse risk, an increased risk of contralateralcancer,
and equivalent survival and metastatic rates [17]. An update
after a followup of 10.5 years conﬁrmed these results, with a
48%reductioninintraductalrecurrencesanda42%decrease
in invasive relapses [18].
3.3. UK/ANZ DCIS Trial. This English study was a multi-
center randomized trial which assessed both the inﬂuence of
WBI and the role of tamoxifen adjuvant treatment following
BCS. Randomization was independent for radiotherapy and
tamoxifen, stratiﬁed by screening center, and blocked in
groups of four [26]. One thousand seven-hundred and one
patients were accrued and one thousand and thirty patients
were randomized to radiotherapy or observation. This trial
has been recently updated after a followup of 12.7 years
[27]. The overall reduction in local relapse was 59%, and
the ipsilateral invasive disease risk reduction was 68%. No
diﬀerence in the number of contralateral cancer cases was
seen. The risk reduction was similar whether patients had
tamoxifen or not.
3.4. SweDCIS Trial. This multicenter Swedish trial enrolled
DCIS patients treated by BCS with tumor-free margins. One
thousand and forty-six women were randomized to either
radiotherapy or no radiotherapy. Once again, the analysis
after a followup of 5.2 years showed a 3-fold reduction in
invasive and in situ local relapses [28]. An updated analysis
published in 2008 conﬁrmed a relative risk reduction of 60%
in local recurrence [29]. Women more than 50 years seemed
to beneﬁt most from adjuvant radiotherapy in this trial, and
the authors concluded that older age should not preclude
DCIS women from radiotherapy.
4. The Role of the Radiotherapy Boost
following BCSandWBI inDCIS
The rationale for dose escalation to the tumor bed relies on
the frequent presence of residual tumor cells in a 10mmInternational Journal of Surgical Oncology 3
radius of the tumor. A dose of 50Gy does not seem to be
high enough to kill such remaining cells. However, wider
excisions with extensive margins signiﬁcantly alter the cos-
metic results. Margins greater than 2 or 3mm are considered
safe, despite a risk of remaining tumor cells of up to 20%
[19,22].ThisrisklegitimatesdoseescalationstudiesinDCIS.
Several retrospective studies have tried to assess the role
of a boost following WBI for DCIS.
An international multicenter retrospective study was
performed on 373 patients, aged 45 years or less, treated in
18 institutions [30]. Forty ﬁve percent of them underwent
WBI, 40% underwent WBI plus a boost, and 15% had no
radiotherapy. The relapse-free survival rates at ten years were
46% without radiotherapy, 72% in the WBI group, and 86%
in the WBI plus boost group. Diﬀerences were statistically
signiﬁcant with an overall risk reduction for local relapse of
66%withWBIand85%withWBIandboost.Inmultivariate
analysis, the margins status and the radiation dose were the
only two independent factors for relapse-free survival. No
diﬀerence in overall survival was found.
Another study by Wong et al. conﬁrmed the favorable
eﬀect of the radiation boost, with no local relapse observed
among 79 patients receiving a boost, whereas 8 of 141
patients in the “no-boost” group experienced in-breast local
recurrence [31]. These results were obtained despite a higher
risk for local relapse in the boost group: 48% (boost group)
versus 8% (no boost group) had positive or less than 1mm
margins.
On the contrary, other reports found no diﬀerence in
local relapse according to the total radiation dose level:
<60Gy versus >60Gy [32], <60Gy versus 60–66Gy versus
>66Gy [13, 33, 34]. In the study by Wai et al., only 50% of
patientshadradiotherapyafterBCS,including35%receiving
WBI without boost and 15% receiving WBI plus a boost to
the lumpectomy bed [35]. Moreover, partial breast boost was
used primarily in subjects with positive or close margins,
which could alter the outcome of these patients and explain
these diﬀerent results. If a retrospective cohort study of 208
DCIS patients with close or focally involved margins after
BCS appeared to show a similar eﬀect of a 16-Gy boost to
that of a reexcision [36], prospective studies are warranted to




Two randomized controlled trials addressing the role of a
16 Gy boost are ongoing, and patients are currently being
recruited.
An international trial of the Trans-Tasman Radiation
Oncology Group, started in 2008, simultaneously evaluates
the role of the boost to the tumor bed and the eﬀect of hypo-
f r a c t i o n a t i o no no u t c o m e si nD C I S .P a t i e n t sa r ed i v i d e d
into 3 strata and randomized within those groups: group
Ai sd e s i g n e dt oe v a l u a t et h ee ﬀect of the boost and of the
fractionation schedule, group B, the boost after 50Gy in 25
fractions of WBI, and group C assesses the interest of the
boost after 42.5Gy in 16 fractions and 22 days of WBI.
In the French multicenter prospective randomized Bon-
bis trial, DCIS women aged 18 and over are randomly
assigned to a 16 Gy boost or no boost, following BCS and
the delivery of 50Gy in 25 fractions to the whole breast
[37]. Nearly half of the patients have been enrolled so far
(900 of the planned 1950 women). Inclusion criteria include
tumor-free margins, the presence of surgical clips in the
lumpectomy bed to ease the boost delivery, and no past
history of cancer. A centralized review of all specimens is
performed,aswellasanassessmentofdummyrunsandtech-
nicalradiotherapycases.Radiotherapyshouldstartwithin12
weeks of surgery. Translational studies investigating candi-
date genes and a predictive test of late toxicity will hopefully
help to individualize patients who can be safely treated with
dose escalation to the tumor bed.
6. Summary
BCS plus WBI is an accepted strategy for DCIS when
mastectomy can be avoided. The eﬀect of a complementary
boosttothetumorbedhasneverbeenprospectivelyassessed.
Two ongoing randomized controlled trials addressing this
issue should help to individualize patients who may beneﬁt
from this treatment.
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